

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

10/660,202 09/11/2003 Om Almarsson TPI-3S0C 23557 75/0 03/25/2008 SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION CL PO BOX 142950 GAINESVILLE, FL 32614-2950 ARTUN 1617	CI 6536 EXAMINER		
SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION OBOX 142950 GAINESVILLE, FL 32614-2950 ARTUNI	EXAMINER		
A PROFESSIONAL ASSOCIATION PO BOX 142950 GAINESVILLE, FL 32614-2950 ARTUN			
GAINESVILLE, FL 32614-2950	CLAYTOR, DEIRDRE RENEE		
1617	IT PAPER NUMBER		
MAIL DA' 03/25/20	TE DELIVERY MOD		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/660,202	ALMARSSON ET AL.	
Examiner	Art Unit	
Renee Claytor	1617	

	Renee Claytor	1617					
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	ress				
THE REPLY FILED 10 March 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
∑ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 3 To F4.1.3.1; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:							
a)  The period for reply expires 6 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (3) or Note of the Period of the Note of the No	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.				
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f), Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any seamed patient term adjustment. See 37 CFR 1.704(b).  NOTICE OF APPEAL							
<ol> <li>The Notice of Appeal was filed on A brief in comp filling the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS</li> </ol>	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the					
3. The proposed amendment(s) filed after a final rejection, to a proposed amendment(s) filed after a final rejection, to a proposed amendment(s) filed further correction (b) They raise the issue of new matter (see NOTE below) (c) They are not deemed to place the application in bett appeal, and/or	nsideration and/or search (see NOT w);	E below);					
(d) ☐ They present additional claims without canceling a c NOTE: (See 37 CFR 1.116 and 41.33(a)).							
<ul> <li>4.  The amendments are not in compliance with 37 CFR 1.12</li> <li>5.  Applicant's reply has overcome the following rejection(s):</li> <li>6.  Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ul>			,				
7. If or purposes of appeal, the proposed amendment(s); a) I how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:		be entered and an ex	planation of				
AFFIDAVIT OR OTHER EVIDENCE  8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).							
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appear and was not earlier presented. Se	and/or appellant fail ee 37 CFR 41.33(d)(1	s to provide a				
<ol> <li>The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER</li> </ol>	n of the status of the claims after er	ntry is below or attach	ed.				
<ol> <li>The request for reconsideration has been considered but see Continuation sheet.</li> </ol>		condition for allowan	ce because:				
12. Note the attached Information Disclosure Statement(s). ( 13. Other:	PTO/SB/08) Paper No(s)						
/SREENI PADMANABHAN/							

Applicants arguments have been fully considered. In particular, Applicants argue that compliance with the written description requirement does not turn on the number of examples provided in the as-field specification. It is noted that claim 1 broadly reads on any solid API and any co-crystal former that is liquid or solid and where the components are hydrogen bonded to one another or the co-crystals with any of the numerous diverse and different co-crystal formers in claim 2 or APIs as in claim 9. There is no description to convey to one of skill in the art that the inventors were in possession of the numerous and diverse oc-crystals as claimed, including any API and any co-crystal former that are hydrogen bonded and are solid or liquid. Therefore, the rejection is maintained.

Applicants arguments over the enablement rejection have been fully considered and are not found persuasive. In particular, Applicants argue that the specification provides adequate teaching to one skilled in the art as to how to make the claims compositions. Applicants argue that a considerable amount of experimentation may be required, but submit that this experimentation is permissible as it is routine and the specification provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed and enables those skilled in the art to practice the invention as claimed. In particular, Applicants argue that the Gavezzotti reference was published 8 years prior to the priority date for the present application and has little relevance. In response to above arguments, it is noted that the specification is enabled for the preparation and use of the particular pharmaceutical co-cytasta as recited in claim 1.7, a discussed in the rejection, the state of the art regarding the formation of different crystalline forms is unpredictable due to the numerous different crystallization factors needed to be controlled to provide different orystal states. Regarding the Gavezzotti reference, it is noted that without proof that the article has no relevance, the content of the article is considered to be substantial to make the argument that the formation and structure of crystals is unpredictable.